• Division Chief, Surgical Oncology, UH Case Medical Center
  • Professor, Surgery, CWRU School of Medicine
  • Chief Medical Officer, UH Seidman Cancer Center
  • Director, Ambulatory Services, UH Seidman Cancer Center

(216)844-7874

Bio

Julian A. Kim, MD, MS, is Chief Medical Officer, UH Seidman Cancer Center, Chief, Division of Surgical Oncology, UH Case Medical Center, Director, Ambulatory Services, UH Seidman Cancer Center, and Charles Hubay Distinguished Professor of Surgery, CWRU School of Medicine.

His areas of expertise include soft tissue cancer (Sarcoma), melanoma, breast cancer, gastrointestinal surgical oncology. He is also an expert in T cell adoptive immunotherapy of cancer and has an active research laboratory.

As Chief Medical Officer, Dr. Kim played a pivotal role in the design, construction and operational phases of the 120 bed, $220 million free-standing UH Seidman Cancer Center (opened June 2011). He oversees hospital inpatient operations in partnership with the Chief Nursing Officer and Vice President of Operations, and manages Medical Directors of inpatient units. Dr. Kim also oversees all hospital accreditation activities.

In his role as Director Ambulatory Services, Dr. Kim oversees operational activities of the Ambulatory Pavilion at UH Seidman Cancer Center. He is a leader in development of multispecialty, disease-based clinics including financial analysis of movement of physicians from doctor’s office to hospital-based practice location. Dr. Kim is also the executive sponsor of the Seidman Quality Program.

As Chief, Oncologic Surgery Services, at UH Seidman Cancer Center, Dr. Kim provides administrative oversight of all cancer surgery services at University Hospitals Case Medical Center. He serves as a representative of Oncology Surgery (32 surgeons) at the Cancer Center Executive Leadership Committee, and leads strategic planning for market share growth of oncology surgery within the University Hospitals Health System.

The overall goal of Dr. Kim’s research effort is to develop immune-based therapies for patients with cancer. He currently holds an Investigational New Drug application with the USFDA and is principal investigator on a Phase I clinical trial of T cell adoptive immunotherapy in patients with advanced melanoma. He has published over 150 manuscripts, book chapters and abstracts, has two US patents and has been funded by the American Cancer Society, Susan Komen Foundation and NIH.

Dr. Kim completed his undergraduate work at Miami University, Oxford, Ohio and earned his medical degree from Medical College of Ohio, where he was elected to the Alpha Omega Alpha Honor Medical Society. He later earned his Master of Science in Clinical Investigation from Case Western Reserve University, Cleveland, Ohio.

Dr. Kim served a surgical residency at University of Maryland Hospitals, Baltimore, MD. He was a Surgical Oncology Fellow at the Arthur G. James Cancer Hospital and Research Institute, Ohio State University, Columbus, OH.

Board Certifications

American Board of Surgery - Surgery

Education & Training

Undergraduate

1982, Miami University

Medical / Professional School(s)

1986, MEDICAL COLLEGE OF OHIO

Internship

1987, General Surgery - University of Maryland Medical Center

Residency

1991, General Surgery - University of Maryland Medical Center

Fellowship

1994, Surgical Oncology - OHIO STATE UNIVERSITY HOSPITAL

Expertise

Bone and Soft Tissue Cancer (Sarcoma), Breast Cancer, Gastrointestinal Surgical Oncology, Gastrointestional Cancer, Malignant Hematology, Mammary Ductoscopy, Melanoma, Melanoma Surgery, Minimally Invasive Breast Surgery, Nipple-Sparing Mastectomy, Sarcoma Surgery, Upper Gastrointestinal Cancer

Office Locations

UH Seidman Cancer Center
(216)844-7874
11100 Euclid Ave
Department of Surgery-Surgical Oncology
Cleveland, OH 44106
Get Directions

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

For calendar year 2013, Julian Kim, MD did not disclose any Outside Relationships with Industry.